AnaptysBio (NASDAQ:ANAB) Given "Buy" Rating at HC Wainwright

AnaptysBio (NASDAQ:ANAB - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $55.00 target price on the biotechnology company's stock. HC Wainwright's price target indicates a potential upside of 154.28% from the company's current price.

ANAB has been the topic of several other research reports. Wedbush restated an "outperform" rating and set a $42.00 price objective on shares of AnaptysBio in a report on Thursday, September 26th. UBS Group lifted their target price on AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a report on Wednesday. Guggenheim lifted their target price on AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a report on Monday, October 21st. JPMorgan Chase & Co. lifted their target price on AnaptysBio from $69.00 to $75.00 and gave the company an "overweight" rating in a report on Wednesday, August 7th. Finally, Truist Financial lifted their target price on AnaptysBio from $20.00 to $30.00 and gave the company a "hold" rating in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $55.73.

AnaptysBio Stock Down 2.5 %

Shares of ANAB stock traded down $0.55 during mid-day trading on Thursday, hitting $21.63. 784,575 shares of the company's stock were exchanged, compared to its average volume of 342,852. AnaptysBio has a fifty-two week low of $13.36 and a fifty-two week high of $41.31. The stock has a 50-day simple moving average of $34.60 and a two-hundred day simple moving average of $29.82. The stock has a market cap of $590.91 million, a price-to-earnings ratio of -3.52 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The business had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. As a group, analysts anticipate that AnaptysBio will post -6.84 earnings per share for the current fiscal year.

Insider Transactions at AnaptysBio

In other AnaptysBio news, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the company's stock in a transaction dated Wednesday, August 14th. The shares were acquired at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the transaction, the insider now owns 7,794,996 shares in the company, valued at $284,517,354. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now directly owns 15,398 shares of the company's stock, valued at approximately $595,440.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ecor1 Capital, Llc bought 273,972 shares of the company's stock in a transaction dated Wednesday, August 14th. The shares were acquired at an average cost of $36.50 per share, for a total transaction of $9,999,978.00. Following the completion of the transaction, the insider now owns 7,794,996 shares of the company's stock, valued at approximately $284,517,354. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 22,440 shares of company stock valued at $892,936. 33.70% of the stock is currently owned by insiders.

Institutional Trading of AnaptysBio

Hedge funds and other institutional investors have recently modified their holdings of the business. Values First Advisors Inc. purchased a new stake in shares of AnaptysBio during the third quarter worth about $49,000. nVerses Capital LLC increased its holdings in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after buying an additional 1,400 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in AnaptysBio in the first quarter valued at about $38,000. Headlands Technologies LLC increased its holdings in AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company's stock valued at $89,000 after buying an additional 2,900 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in AnaptysBio by 81.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company's stock valued at $195,000 after buying an additional 2,600 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.